Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
May 17, 2019 • 9:00 AM EDT
Ligand Licenses VER250840 to Cumulus Oncology
May 6, 2019 • 9:00 AM EDT
Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.
May 2, 2019 • 4:01 PM EDT
Ligand Reports First Quarter 2019 Financial Results
May 2, 2019 • 4:30pm EDT
See all events
Apr 9, 2019
Mar 18, 2019 • 4:30pm EDT
Laguna Niguel, California
May 29, 2019
Jun 6, 2019 • 8:30am PDT
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121
Immunovant initiates dosing in ASCEND-GO 1, a Phase 2a trial of OmniAb-derived IMVT-1401 in patients with Graves’ O… https://t.co/Pa39HvSs7O
Corvus provides update on ciforadenant (CPI-444); enrollment continues for two Phase 1b/2 trials https://t.co/oT5wyfCG6K
Daiichi Sankyo launches MINNEBRO® (esaxerenone) tablets in Japan https://t.co/17rilBZ53J